hrp0095p1-238 | Diabetes and Insulin | ESPE2022

Faster-acting insulin Fiasp vs insulin Novorapid in type 1 diabetes children and adolescents with sensor-augmented pump therapy

Xatzipsalti Maria , Triantafillidou Antigoni , Kourousi Giannoula , Patouni Konstantina , Bourousis Evangelos , Kassari Elisavet , Delis Dimitrios , Vazeou Andriani

Introduction: Rapid-acting insulin analogues have been developed to mimic more closely the physiological action of endogenous insulin. However, they still have a delayed onset of action and a longer duration compares to endogenous insulin. Therefore, newer insulin analogues have been developed with a faster onset and a shorter duration of action.Aim: To evaluate the efficacy of rapid-acting insulin analogues (Novorapid) ...

hrp0082p3-d2-827 | Growth (1) | ESPE2014

Impairment of Glucose Metabolism in GH Deficient Children Under GH Replacement

Xatzipsalti Maria , Mitravela Vasiliki-Ioanna , Polichroni Ioulia , Delis Dimitrios , Vazeou Andriani , Stamogiannou Lela

Background: GH replacement therapy in children with GH deficiency (GHD) mainly promotes linear growth. There are few studies fully analyzed the metabolic consequences of GH therapy.Objective and hypotheses: To study the effects of GH replacement therapy on glucose metabolism in patients with GHD.Method: Sixty two children {mean age (S.D. 8.6 (3.3,) years; 35 boys, 10 SGA, 50 prepubertal who were under treatment with ...